A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

Active:	Yes
Cancer Type:	Lung Cancer	NCT ID:	NCT05211895
Trial Phases:	Phase III	Protocol IDs:	D9075C00001 (primary) NCI-2023-06450 2021-004327-32
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	AstraZeneca Pharmaceuticals LP
NCI Full Details:	http://clinicaltrials.gov/show/NCT05211895

Summary

This is a Phase III, randomised, double-blind, placebo-controlled, multicentre,
international study assessing the efficacy and safety of durvalumab (MEDI4736) and
domvanalimab (AB154) compared with durvalumab plus placebo in adults with locally
advanced (Stage III), unresectable NSCLC whose disease has not progressed following
definitive platinum-based cCRT.

Treatment Sites in Georgia

Northside Hospital Cancer Institute
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-303-3355
www.northside.com

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.